32 Live Notices for Infliximab Tenders
Showing 1 to 20
Delivery Of Biological Drugs As Part Of Drug Programs
17 Jul 2025
18 Aug 2025Request For International Offers To Purchase Hospital Medicines For The Year 2026-2027 (I/2027-2026)
Specific Contract For The Supply Of Exclusive And/Or Infungable Drugs Through The Use Of The Sintel Platform, Pursuant To Art. 55, Paragraph 8 Of Legislative Decree 50/2016, As Part Of The Dynamic Acquisition System Called Aria2020305 "Dynamic Acquisition System For Supplies Of Pharmaceutical Products" - 5Th Procedure Year 2025
Procurement Of Biological Medicine In No Induced Indications - Infliximab
Biological Therapy And Eltrombopag
Bidding Ad For: Directorate Of The National Institute Of Health Management (Ingesa). Object: Framework Agreement For The Supply, Environmental Respectful, Of Biological Medicines With Biosimilar, For Several Autonomous Communities, Centers Of The National Institute Of Health Management (Ingesa) In Ceuta And Melilla And State Administration Agencies. File: Am 2025/034.
Framework Agreement For The Supply, Respectful Of The Environment, Of Biological Medicines With Biosimilar, For Several Autonomous Communities, Centers Of The National Institute Of Health Management (Ingesa) In Ceuta And Melilla And State Administration Organizations
Completion Of A Non-Exclusive Discount Contract According To Section 130A (8) Sgb V On Pharmaceuticals With The Active Ingredient Infliximab (Atc Code: L04Ab02).
Completion Not Excl. Pharmaceutical Discount Club. According To Section 130A (8) Sgb V By Means Of An Open House Model To The Active Ingredient Infliximab (Atc Code According To Who: L04Ab02)
Completion Not Excl. Pharmaceutical Discount Club. According To Section 130A (8) Sgb V By Means Of An Open House Model To The Active Ingredient Infliximab (Atc Code According To Who: L04Ab02)
Completion Of Non-Exclusive Discount Agreements According To § 130 A (8) Sgb V With The Active Ingredient Infliximab For Subcutaneous Application
Completion Of Non-Exclusive Discount Agreements According To § 130 A (8) Sgb V With The Active Ingredient Infliximab For Intravenous Application
Completion Of Non-Exclusive Discount Agreements According To § 130 A (8) Sgb V With The Active Ingredient Infliximab For Subcutaneous Application
Open House Biologics Discount Agreements 2025-01 - Infliximab
Open House Biologics Discount Agreements 2025-01 - Infliximab
Environmentally Friendly Supply Of Biological Human Medicines With Biosimilars For Public Health Centres In Valencia
Conclusion Of Non-Exclusive Discount Agreements According To §130A Para.8 Sgb V For Various Active Ingredients/Combinations With The Possibility Of Conclusion At Any Time Within The Framework Of The So-Called Open House Procedure
Conclusion Of Non-Exclusive Discount Agreements According To §130A Para.8 Sgb V For Various Active Ingredients/Combinations With The Possibility Of Conclusion At Any Time Within The Framework Of The So-Called Open House Procedure
Conclusion Of A Non-Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V By Means Of An Open-House Model For The Active Ingredient Infliximab For Subcutaneous Injection (Atc Code According To Who: L04Ab02)
Pharmaceutical Discount Agreements From 01.01.2025 For Various Active Ingredients Within The Framework Of An Open-House Procedure
Tenders by Country